Patents Represented by Attorney Robert J. Driscoll

Find this attorney in the Justia Lawyer Directory

  • Transgenic mice containing magnesium-dependent protein phosphatase gene disruptions
    Patent number: 6858772
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in the magnesium-dependent protein phosphatase gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: February 22, 2005
    Assignee: Deltagen, Inc.
    Inventor: Keith D. Allen
  • Methods of creating constructs useful for introducing sequences into embryonic stem cells
    Patent number: 6815185
    Abstract: This invention provides novel nucleotide constructs. Also provided are methods for making DNA constructs useful for introducing sequences into and disrupting the function of a gene in a cell, particularly an embryonic stem cell.
    Type: Grant
    Filed: June 19, 2001
    Date of Patent: November 9, 2004
    Inventors: Robert D. Klein, Thomas J. Brennan
  • Transgenic mice containing NPY6-R neuropeptide receptor gene disruptions
    Patent number: 6765126
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a NPY6 receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: July 20, 2004
    Assignee: Deltagen Inc.
    Inventor: Keith D. Allen
  • Transgenic mice containing intestinal alkaline phosphatase gene disruptions
    Patent number: 6762342
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an intestinal alkaline phosphatase gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: July 13, 2004
    Assignee: Deltagen, Inc.
    Inventor: Keith D. Allen
  • Transgenic mice containing retina-specific nuclear receptor gene disruptions
    Patent number: 6730821
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in genes, which are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: May 4, 2004
    Assignee: Deltagen, Inc.
    Inventor: Catherine Guenther
  • Transgenic mice containing DEZ orphan receptor gene disruptions
    Patent number: 6717032
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a DEZ receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: April 6, 2004
    Assignee: Deltagen, Inc
    Inventor: Thomas J. Brennan
  • Transgenic mice exhibiting increased susceptibility to seizures
    Patent number: 6653526
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a ubiquitin-specific protease 16 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: November 25, 2003
    Assignee: Deltagen, Inc.
    Inventor: Michael W. Leviten